Cargando…
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
BACKGROUND: MEDI8897 is a recombinant human monoclonal antibody being developed for prophylaxis of serious respiratory syncytial virus (RSV) disease in all infants. METHODS: In this phase 1b/2a dose-escalation study, healthy preterm infants with a gestational age of 32–35 weeks were randomized to re...
Autores principales: | Domachowske, Joseph B., Khan, Anis A., Esser, Mark T., Jensen, Kathryn, Takas, Therese, Villafana, Tonya, Dubovsky, Filip, Griffin, M. Pamela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133204/ https://www.ncbi.nlm.nih.gov/pubmed/29373476 http://dx.doi.org/10.1097/INF.0000000000001916 |
Ejemplares similares
-
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
por: Griffin, M. Pamela, et al.
Publicado: (2017) -
A Single Dose Monoclonal Antibody (mAb) Immunoprophylaxis Strategy to Prevent RSV Disease in All Infants: Results of the First in Infant Study with MEDI8897
por: Domachowske, Joseph B, et al.
Publicado: (2017) -
901. MEDI8897 Prevents Serious RSV Disease in Healthy Preterm Infants
por: Pamela Griffin, Mary, et al.
Publicado: (2019) -
Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses
por: Falloon, Judith, et al.
Publicado: (2017) -
An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults
por: Falloon, Judith, et al.
Publicado: (2017)